1. Volume 52, Issue 4, Pages 1195-1203 (October 2007)
Treatment Outcomes in the STAR Study: A Subanalysis of Solifenacin 5 mg and Tolterodine ER 4 mg 
Christopher R. Chapple, Aino Fianu-Jonsson, Mark Indig, Vik Khullar, José Rosa, Roberto M. Scarpa, Arun Mistry, D. Mark Wright, John Bolodeoku 
European Urology 
Volume 52, Issue 4, Pages (October 2007)
DOI: /j.eururo
Copyright © 2007 European Association of Urology Terms and Conditions

2. Fig. 1
Comparison of OAB improvements (and pad use) after 4 weeks active treatment (Randomised Treatment groups). Sol=solifenacin; tol=Tolterodine ER.
European Urology  , DOI: ( /j.eururo )
Copyright © 2007 European Association of Urology Terms and Conditions

3. Fig. 2
Comparison of OAB improvements (and pad use) at endpoint for NDI subgroups (treatment subgroups not requesting a dose increase). Endpoint=12 weeks or last clinic visit; NDI=No Does Increase.
European Urology  , DOI: ( /j.eururo )
Copyright © 2007 European Association of Urology Terms and Conditions